Literature DB >> 20818322

Prostate cancer. Saturation biopsy does not accurately localize tumors.

Oliver Sartor1.   

Abstract

Precise localization of prostate cancer is essential for the success of focal therapies. Despite suggestions that saturation biopsy might be useful in this regard, a new study implies it cannot accurately pinpoint prostate tumors. research efforts would perhaps be better focused on identifying which patients require treatment for clinically localized prostate cancer in the first place.

Entities:  

Mesh：

Year:  2010        PMID： 20818322     DOI： 10.1038/nrurol.2010.139

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  9 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Michael W Kattan; Darko Pucar; Kentaro Kuroiwa; Hui-Ni Chen; Jessica Spector; Jason A Koutcher; Kristen L Zakian; Peter T Scardino
Journal:  BJU Int       Date:  2007-01-12       Impact factor: 5.588

3.  Candidate selection for prostate cancer focal therapy.

Authors:  Samir S Taneja; Malcolm Mason
Journal:  J Endourol       Date:  2010-05       Impact factor: 2.942

4.  Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.

Authors:  Sara M Falzarano; Ming Zhou; Adrian V Hernandez; Ayman S Moussa; J Stephen Jones; Cristina Magi-Galluzzi
Journal:  Urology       Date:  2010-03-05       Impact factor: 2.649

5.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta").

Authors:  Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

8.  Evaluating localized prostate cancer and identifying candidates for focal therapy.

Authors:  A Oliver Sartor; Hedvig Hricak; Thomas M Wheeler; Jonathan Coleman; David F Penson; Peter R Carroll; Mark A Rubin; Peter T Scardino
Journal:  Urology       Date:  2008-12       Impact factor: 2.649

9.  A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.

Authors:  C Parker; D Muston; J Melia; S Moss; D Dearnaley
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640
  9 in total
  1 in total

Review 1.  Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Authors:  Yoshiyuki Kakehi
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.